



PEGASUS ANNOUNCES SHARE CONSOLIDATION

Vancouver: January 24, 2024 – Pegasus Mercantile Inc. (formerly Xtacy Therapeutics Corp.) (CSE: LOAN) (Frankfurt: TT5) (OTC: XTCYF) (“the Company”) announces that the Company intends to consolidate the common shares in the capital of the Company (the “Common Shares”) on the basis of five (5) pre-consolidation Common Shares for every one (1) post-consolidation Common Share (the “Consolidation”).

The Company currently has 58,156,971 Common Shares issued and outstanding, and following the Consolidation, the Company will have approximately 11,631,394 Common Shares issued and outstanding, prior to rounding for fractional shares.

The Consolidation was approved by the board of directors of the Company (the “Board”) in accordance with the Articles of the Company, but remains subject to the approval of the Canadian Securities Exchange (the “Exchange”). The Company will issue a further news release announcing the effective date of the Consolidation upon receiving Exchange approval. The Company will not be changing its name in conjunction with the Consolidation.

About Pegasus Mercantile:

Pegasus is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for consumer products . The focus of the Company has been on global wellness and healthcare-related target companies.

For further information visit website:

www.pegasusmercantile.com
Contact Meris Kott CEO
info@pegasusmercantile.com
(561) 212-3323

Further information about the Company is available on www.SEDARplus.com under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.